title: The role of solithromycin in the management of bacterial community-acquired pneumonia.
abstract: The fluoroketolide solithromycin is 2-fold more potent in vitro than telithromycin against pneumococci (including macrolide-resistant strains) and Haemophilus influenzae and very active on pathogens causing atypical pneumonia. In contrast, it is a 30-fold less potent inhibitor of nicotinic receptors incriminated in telithromycin toxicity. In Phase II/III trials, oral solithromycin once-daily (800 mg on day 1; 400 mg on days 2-5) proved effective and safe when compared to respiratory fluoroquinolones for the treatment of community-acquired bacterial pneumonia (CABP). A Phase III intravenous trial vs. moxifloxacin has been recently completed for the same indication. Solithromycin may restore interest in ketolides as a first-line therapy for CAPB. Solithromycin safety should nevertheless be confirmed in larger populations allowing for detection of rare adverse events.
authors: a Pharmacologie cellulaire et moléculaire , Louvain Drug Research Institute, Université catholique de Louvain , Brussels , Belgium.
authors: Françoise
authors: F
authors: Van Bambeke
authors: a Pharmacologie cellulaire et moléculaire , Louvain Drug Research Institute, Université catholique de Louvain , Brussels , Belgium.
authors: Paul M
authors: PM
authors: Tulkens
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy*; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides; D014230:Triazoles; C547755:solithromycin
keywords: Chlamydophila pneumoniae; Haemophilus influenzae; Legionella pneumophila; Mycoplasma pneumoniae; Streptococcus pneumoniae; community-acquired bacterial pneumonia; ketolide; levofloxacin; moxifloxacin; solithromycin